buyWeak
John Patience bought $314k of AXDX
director at Accelerate Diagnostics, Inc. 200,000 shares at an average of $1.57, traded Dec 3, 2024, filed Dec 3, 2024.
Conviction score
35Value
$314k
200,000 shares
Holdings after
653,224
+44% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +14Trade size$314k at market
- +6Relative to holdingsHoldings up 44%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-125217, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 3, 2024 | POpen-market purchase Common Stockindirect: By John Patience Living Trust dated 7/23/1993 | +200,000 | $1.57 | $314k | 653,224 | Dec 3, 2024 |
Related signals
Other insiders at Accelerate Diagnostics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Accelerate Diagnostics, Inc | Larry Michael Mertz Chief Technology Officer | $990 1,523 shares | -2% | |
| 30Weak | Accelerate Diagnostics, Inc | Jack Phillips Chief Executive Officer | $16k 25,343 shares | -12% | |
| 22Weak | Accelerate Diagnostics, Inc | David Patience Chief Financial Officer | $4,839 6,816 shares | -10% | |
| 7Weak | AXDXsell Accelerate Diagnostics, Inc | David Patience Chief Financial Officer | $583 535 shares | -1% | |
| 10Weak | AXDXsell Accelerate Diagnostics, Inc | Jack Phillips Chief Executive Officer | $655 485 shares | -0% | |
| 29Weak | AXDXsell Accelerate Diagnostics, Inc | Jack W Schuler director, owner | $314k 200,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.